{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["25(6)"],"submitter":["Caulley L"],"pubmed_abstract":["<h4>Purpose</h4>The objective of this study was to compare the cost-effectiveness of preoperative octreotide therapy followed by surgery versus the standard treatment modality for growth-hormone secreting pituitary adenomas, direct surgery (that is, surgery without preoperative treatment) from a public third-party payer perspective.<h4>Methods</h4>We developed an individual-level state-transition microsimulation model to simulate costs and outcomes associated with preoperative octreotide therapy followed by surgery and direct surgery for patients with growth-hormone secreting pituitary adenomas. Transition probabilities, utilities, and costs were estimated from recent published data and discounted by 3% annually over a lifetime time horizon. Model outcomes included lifetime costs [2020 Uni"],"journal":["Pituitary"],"pagination":["868-881"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9675692"],"repository":["biostudies-literature"],"pubmed_title":["Cost-effectiveness of direct surgery versus preoperative octreotide therapy for growth-hormone secreting pituitary adenomas."],"pmcid":["PMC9675692"],"pubmed_authors":["Alkherayf F","Doyle MA","Quinn J","Thavorn K","Schramm D","Caulley L","Krijkamp E","Johnson-Obaseki S","Dong SX","Hunink MGM","Sahlollbey N","Kilty SJ"],"additional_accession":[]},"is_claimable":false,"name":"Cost-effectiveness of direct surgery versus preoperative octreotide therapy for growth-hormone secreting pituitary adenomas.","description":"<h4>Purpose</h4>The objective of this study was to compare the cost-effectiveness of preoperative octreotide therapy followed by surgery versus the standard treatment modality for growth-hormone secreting pituitary adenomas, direct surgery (that is, surgery without preoperative treatment) from a public third-party payer perspective.<h4>Methods</h4>We developed an individual-level state-transition microsimulation model to simulate costs and outcomes associated with preoperative octreotide therapy followed by surgery and direct surgery for patients with growth-hormone secreting pituitary adenomas. Transition probabilities, utilities, and costs were estimated from recent published data and discounted by 3% annually over a lifetime time horizon. Model outcomes included lifetime costs [2020 Uni","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-25T21:05:17.528Z","creation":"2025-04-06T08:35:20.628Z"},"accession":"S-EPMC9675692","cross_references":{"pubmed":["36030360"],"doi":["10.1007/s11102-022-01270-8"]}}